RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system

Journal of Controlled Release

Volumn 173, Issue 1, 2014, Pages 110-118

  Sakurai, Yu ^a   Hatakeyama, Hiroto ^a   Sato, Yusuke ^a   Hyodo, Mamoru ^a   Akita, Hidetaka ^a   Ohga, Noritaka ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Active targeting; Anti angiogenic therapy; Cyclic RGD; Liposome; siRNA

Indexed keywords

ACTIVE TARGETING; ANTI-ANGIOGENIC THERAPY; CYCLIC RGD; INTRAVENOUS INJECTIONS; RAPID AMPLIFICATION OF CDNA ENDS; SIRNA; SMALL INTERFERING RNA (SIRNA); VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ENDOTHELIAL CELLS; GENE EXPRESSION; GENETIC ENGINEERING; LIGANDS; LIPOSOMES; POLYMERASE CHAIN REACTION; RNA; THERMOELECTRICITY; TUMORS;

GENE THERAPY;

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; COMPLEMENTARY DNA; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO PHENYLLYSYL) MEND; LIGAND; LIPOSOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; YSK 05; YSK MEND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TUMOR LEVEL; ENCAPSULATION; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIGAND BINDING; LIPOSOMAL DELIVERY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ACTIVE TARGETING; ANTI-ANGIOGENIC THERAPY; CYCLIC RGD; LIPOSOME; SIRNA;

ANIMALS; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPIDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; PIPERIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84887709462     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.10.003     Document Type: Article

References (43)

1. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974 (Pubitemid 43093963)
2. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat. Rev. Cancer 8 2008 579 591
3. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
4. C. Harrison Angiogenesis: a deeper understanding of VEGFR inhibitors Nat. Rev. Cancer 12 2012 735
5. C. Harrison Anticancer drugs: a deeper understanding of VEGFR inhibitors Nat. Rev. Drug Discov. 11 2012 831
6. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
7. G.R. Rettig, and M.A. Behlke Progress toward in vivo use of siRNAs-II Mol. Ther. 20 2012 483 512
8. K. Kogure, H. Akita, Y. Yamada, and H. Harashima Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system Adv. Drug Deliv. Rev. 60 2008 559 571 (Pubitemid 351215573)
9. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
10. Y. Sato, H. Hatakeyama, Y. Sakurai, M. Hyodo, H. Akita, and H. Harashima A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo J. Control. Release 163 2012 267 276
11. Y. Sakurai, H. Hatakeyama, Y. Sato, M. Hyodo, H. Akita, and H. Harashima Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system Mol. Ther. 2 2013 1195 1203
12. A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, and I. MacLachlan Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice J. Clin. Invest. 119 2009 661 673
13. S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, D.W. Sah, D. Stebbing, E.J. Crosley, E. Yaworski, I.M. Hafez, J.R. Dorkin, J. Qin, K. Lam, K.G. Rajeev, K.F. Wong, L.B. Jeffs, L. Nechev, M.L. Eisenhardt, M. Jayaraman, M. Kazem, M.A. Maier, M. Srinivasulu, M.J. Weinstein, Q. Chen, R. Alvarez, S.A. Barros, S. De, S.K. Klimuk, T. Borland, V. Kosovrasti, W.L. Cantley, Y.K. Tam, M. Manoharan, M.A. Ciufolini, M.A. Tracy, A. de Fougerolles, I. MacLachlan, P.R. Cullis, T.D. Madden, and M.J. Hope Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172 176
14. M. Meyer, A. Philipp, R. Oskuee, C. Schmidt, and E. Wagner Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery J. Am. Chem. Soc. 130 2008 3272 3273 (Pubitemid 351456015)
15. H. Yu, Y. Zou, Y. Wang, X. Huang, G. Huang, B.D. Sumer, D.A. Boothman, and J. Gao Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery ACS Nano 5 2011 9246 9255
16. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160 (Pubitemid 40282557)
17. C.J. Avraamides, B. Garmy-Susini, and J.A. Varner Integrins in angiogenesis and lymphangiogenesis Nat. Rev. Cancer 8 2008 604 617
18. C. Mas-Moruno, F. Rechenmacher, and H. Kessler Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anticancer Agents Med. Chem. 10 2010 753 768
19. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, and D.A. Cheresh Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
20. F. Danhier, A. Le Breton, and V. Preat RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis Mol. Pharm. 9 2012 2961 2973
21. R.J. Christie, Y. Matsumoto, K. Miyata, T. Nomoto, S. Fukushima, K. Osada, J. Halnaut, F. Pittella, H.J. Kim, N. Nishiyama, and K. Kataoka Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection ACS Nano 6 2012 5174 5189
22. E. Kenjo, T. Asai, N. Yonenaga, H. Ando, T. Ishii, K. Hatanaka, K. Shimizu, Y. Urita, T. Dewa, M. Nango, H. Tsukada, and N. Oku Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy Biol. Pharm. Bull. 36 2013 287 291
23. T. Tagami, T. Suzuki, M. Matsunaga, K. Nakamura, N. Moriyoshi, T. Ishida, and H. Kiwada Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery Int. J. Pharm. 422 2012 280 289
24. S. Anand, B.K. Majeti, L.M. Acevedo, E.A. Murphy, R. Mukthavaram, L. Scheppke, M. Huang, D.J. Shields, J.N. Lindquist, P.E. Lapinski, P.D. King, S.M. Weis, and D.A. Cheresh MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis Nat. Med. 16 2010 909 914
25. D.Y. Heng, and R.M. Bukowski Anti-angiogenic targets in the treatment of advanced renal cell carcinoma Curr. Cancer Drug Targets 8 2008 676 682
26. B. Escudier Emerging immunotherapies for renal cell carcinoma Ann. Oncol. 23 Suppl. 8 2012 viii35 viii40
27. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
28. J.S. Ko, P. Rayman, J. Ireland, S. Swaidani, G. Li, K.D. Bunting, B. Rini, J.H. Finke, and P.A. Cohen Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res. 70 2010 3526 3536
29. I. Helfrich, I. Scheffrahn, S. Bartling, J. Weis, V. von Felbert, M. Middleton, M. Kato, S. Ergun, and D. Schadendorf Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J. Exp. Med. 207 2010 491 503
30. G. Kibria, H. Hatakeyama, N. Ohga, K. Hida, and H. Harashima Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery J. Control. Release 153 2011 141 148
31. N. Ohga, K. Hida, Y. Hida, C. Muraki, K. Tsuchiya, K. Matsuda, Y. Ohiro, Y. Totsuka, and M. Shindoh Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells Cancer Sci. 100 2009 1963 1970
32. H. Maeda, Y. Matsumura, and H. Kato Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer J. Biol. Chem. 263 1988 16051 16054 (Pubitemid 18262016)
33. R.A. Brekken, J.P. Overholser, V.A. Stastny, J. Waltenberger, J.D. Minna, and P.E. Thorpe Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice Cancer Res. 60 2000 5117 5124
34. I.J. Duignan, E. Corcoran, A. Pennello, M.J. Plym, M. Amatulli, N. Claros, M. Iacolina, H. Youssoufian, L. Witte, S. Samakoglu, J. Schwartz, D. Surguladze, and J.R. Tonra Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models Neoplasia 13 2011 49 59
35. K. Sou, T. Endo, S. Takeoka, and E. Tsuchida Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles Bioconjug. Chem. 11 2000 372 379 (Pubitemid 30324903)
36. P. Vaupel, F. Kallinowski, and P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review Cancer Res. 49 1989 6449 6465 (Pubitemid 20008770)
37. A.R. Pries, A.J. Cornelissen, A.A. Sloot, M. Hinkeldey, M.R. Dreher, M. Hopfner, M.W. Dewhirst, and T.W. Secomb Structural adaptation and heterogeneity of normal and tumor microvascular networks PLoS Comput. Biol. 5 2009 e1000394
38. F. Bianchini, N. Cini, A. Trabocchi, A. Bottoncetti, S. Raspanti, E. Vanzi, G. Menchi, A. Guarna, A. Pupi, and L. Calorini (1)(2)(5)I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of alphavbeta(3) integrin as a molecular imaging probe for angiogenesis J. Med. Chem. 55 2012 5024 5033
39. Y. Aoki, S. Hosaka, S. Kawa, and K. Kiyosawa Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif Cancer Gene Ther. 8 2001 783 787 (Pubitemid 32983134)
40. T. Eisen, C.N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, and B. Escudier Targeted therapies for renal cell carcinoma: review of adverse event management strategies J. Natl. Cancer Inst. 104 2012 93 113
41. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, D. Fukumura, and R.K. Jain Normalization of the vasculature for treatment of cancer and other diseases Physiol. Rev. 91 2011 1071 1121
42. F. Mitjans, T. Meyer, C. Fittschen, S. Goodman, A. Jonczyk, J.F. Marshall, G. Reyes, and J. Piulats In vivo therapy of malignant melanoma by means of antagonists of alphav integrins Int. J. Cancer 87 2000 716 723 (Pubitemid 30620415)
43. M.A. Buerkle, S.A. Pahernik, A. Sutter, A. Jonczyk, K. Messmer, and M. Dellian Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo Br. J. Cancer 86 2002 788 795 (Pubitemid 34250824)